Summit Therapeutics Inc. Common Stock trailing returns
Summit Therapeutics Inc. Common Stock's 10-year return is +6.3% a year (CAGR) (+84.9% cumulative). How Summit Therapeutics Inc. Common Stock (SMMT) has performed over the last day, week, month and year, over 5, 10 and 20 years, and since inception, through October 2, 2026 — cumulative and annualized, with dividends on or off.
Trailing returns by period#
To 2026-10-02. Annualized (CAGR) for windows of a year or more.
| Period | Path | Annualized | Cumulative |
|---|---|---|---|
| 1 day | — | +0.4% | |
| 5 days | — | +7.4% | |
| 1 month | — | +14.8% | |
| YTD | — | -4.2% | |
| 1 year | -19.7% | -19.7% | |
| 5 years | +26.8% | +228.0% | |
| 10 years | +6.3% | +84.9% | |
| Since inception (2015) | +4.4% | +64.5% |
Growth of SMMT
Actual index level (solid); dashed lines are each window's constant-rate path from start to today.
Methodology#
Trailing returns measure from the closest close about N years before the latest close (2026-10-02). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Total return reinvests dividends (from SMMT's split- and dividend-adjusted closes); price return excludes them. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.
FAQ#
- What is Summit Therapeutics Inc. Common Stock's 10-year return?
- Over the last 10 years, Summit Therapeutics Inc. Common Stock (SMMT) returned about +6.3% a year annualized (+84.9% cumulative total return).
- What is Summit Therapeutics Inc. Common Stock's return since inception?
- Since 2015, Summit Therapeutics Inc. Common Stock (SMMT) has compounded at about +4.4% a year — +64.5% in total.